Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 11/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 10/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431418 | 0.80 | STK17B (0.43) | STK17BMAP3K8STK17A | |
| SCHEMBL20588620 | 0.76 | CYP2A6 (0.32) | ALDH1A1 | |
| SCHEMBL4799418 | 0.76 | ALDH1A1 (0.42) | STK17BMAP3K8STK17AALDH1A1LMNA | |
| SCHEMBL1847722 | 0.75 | NPC1 (0.43) | STK17BMAP3K8ALDH1A1 | |
| SCHEMBL4467490 | 0.74 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL6221009 | 0.69 | STK17B (0.48) | STK17BMAP3K8STK17A | |
| SCHEMBL10272368 | 0.67 | GRIN2D (0.41) | ALDH1A1LMNA | |
| SCHEMBL4801809 | 0.66 | STK17B (0.41) | STK17BMAP3K8STK17A | |
| SCHEMBL23356001 | 0.65 | GRIN3B (0.44) | ALDH1A1 | |
| SCHEMBL2233009 | 0.65 | ALDH1A1 (0.33) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | STK17B 3419/4885MAP3K8 4175/4885STK17A 2491/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | STK17B 3376/4885MAP3K8 1634/4885STK17A 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.